Project Grant HT94252510565
Award Date
8/15/25
Completion Date
8/14/28
Dollars Obligated
$932K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
The federal Project Grant award of $718,858.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award was granted to The University of Texas M.D. Anderson Cancer Center on February 15, 2025, with a planned completion date of February 14, 2028. As a leading academic cancer research institution, M.D....
The University of Texas MD Anderson Cancer Center received a $729,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing novel strategies for immunoprevention of estrogen receptor-negative breast cancer. The three-year award, issued on December 31, 2021 with a completion date of December 30, 2024, will fund applied and advanced biomedical research...
The University of Texas MD Anderson Cancer Center will receive $2,429,996 under a Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program to investigate molecular origins and therapeutic implications of DNA damage-triggered innate immune responses in breast cancer. The three-year award beginning September 1, 2022 will support research exploiting molecular pathways involved in DNA damage response signaling to develop novel...
This federal Project Grant award of $505,071.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The University of Texas M.D. Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award period runs from February 15, 2025 to February 14, 2028. The Military Medical Research and Development program funds diverse biomedical research...
The federal Project Grant award of $728,043 was granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to The University of Texas M.D. Anderson Cancer Center in Houston, TX. The funding will support research to delineate the tumor ecology and genomic progression of lobular breast cancers over a period of 3 years from February 2025 to January 2028. This research aims to transform healthcare for military service members, veterans, and the...
The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...